Background Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. One
of the main challenges in the management of OC is the late clinical presentation of disease …

Ovarian cancer (OC) is a heterogeneous disease with the highest mortality rate and the
poorest prognosis among gynecological malignancies. Because of the absence of specific …

Simple Summary Ovarian cancer is a lethal disease in women with a 10-year survival rate
of< 40% worldwide. A key molecular alteration in ovarian cancer is the aberrant …

Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer,
contributing to the high mortality-to-incidence ratio. Management of the platinum-resistant …

Focal adhesion kinase (FAK; encoded by PTK2) was discovered over 30 years ago as a
cytoplasmic protein tyrosine kinase that is localized to cell adhesion sites, where it is …

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in
human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous …

Introduction The poor prognosis of ovarian carcinoma (OvC) is due to the advanced stage at
diagnosis, a high risk of relapse after first-line therapies, and the lack of efficient treatments …

Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of
response to treatment in patients with high grade serous ovarian carcinoma (HGSOC). TP53 …

Ovarian cancer is the deadliest gynecological cancer. 70% of the cases are diagnosed at
late stages with already developed metastases due to the absence of easily noticeable …

High-grade serous ovarian cancer (HGSC) is the most common subtype of ovarian cancer.
HGSC patients typically present with advanced disease, which is often resistant to …